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Combined administration of IgA and IgG anti-Thy-1 antibod- the renal biopsies, respectively [3]. Simultaneous deposi-
ies enhances renal inflammation in rats. tion of different immunoglobulin isotypes in the mesan-
Background. IgA nephropathy (IgAN) is the most common gial area is often associated with a more rapid declinetype of immunologically mediated glomerulonephritis (GN)
of renal function when compared with patients with IgAand is characterized by deposition in the glomerular mesangium
deposits alone [4]. This is reflected by an increased pro-of IgA together with C3, C5b-9, and properdin. In patients,
the codeposition of IgA together with IgG and/or IgM can teinuria [5] and a concurrent increase in the degree of
lead to a more progressive course of disease. In Wistar rats, complement activation [4].
mesangial proliferative GN can be induced by the injection of Thus far, a number of animal studies have ascertained
mouse IgG anti-Thy-1 antibodies (ER4G). In contrast, the
that pIgA in the mesangial area can lead to inflammation.administration of mouse IgA anti-Thy-1 antibodies (ER4A)
However, oral immunization of mice with food antigensto rats results in isolated hematuria without detectable albu-
minuria and without detectable complement deposition. such as ferritin or ovalbumin [6] is not representative
Methods. To investigate the effect of the combination of for the human situation because the food antigens used
IgA and IgG on glomerular injury, Wistar rats were injected in these studies deposit in mouse glomeruli, unlike the
with a limiting dose of ER4G in the presence or absence of
situation in patients with IgAN. Injection of mice withER4A in a dose able to induce hematuria.
preformed IgA-immune complexes or pIgA in combina-Results. Although the limiting dose of ER4G or the dose
of ER4A used did not induce significant albuminuria, the com- tion with antigen [7] also results in mesangial deposition
bination of ER4G and ER4A resulted in a synergistic increase of IgA. However, the relative contribution of IgA im-
in albuminuria. Microhematuria occurred in rats receiving ei- mune complex (IC) or pIgA in IgAN disease pathogene-
ther ER4A or ER4G alone or in combination. Although both
sis cannot be readily made because the precise nature ofER4A or a limiting dose of ER4G induced minor increases in
the antigens in the immune complex is thus far unknown.extracellular matrix expansion, the combination resulted in a
pronounced, additive increased matrix expansion. Inhibition of IgA clearance through the liver in mice
Conclusion. We conclude that in this model of IgA-mediated results in the deposition of IgA in the renal mesangium
glomerulopathy, a selective complement-dependent synergistic [8], but only one study reported a slower elimination
renal injury is induced in Wistar rats by glomerular codeposi-
rate of IgA–IgG aggregates in patients with IgAN [9].tion of mouse anti-Thy-1 monoclonal isotypes.
Finally, in these studies, mice exhibited variable immu-
nohistochemical alterations, which makes the reproduc-
ibility of these experimental models questionable.IgA nephropathy (IgAN) is the most common immu-
Thus, we decided to create a new model for IgANnologically mediated form of glomerulonephritis (GN)
involving monoclonal mouse IgA anti-Thy-1 antibodiesworldwide. Glomerular mesangial deposits containing
(ER4A) [10], which bind specifically to Thy-1, a trans-mainly polymeric IgA (pIgA) [1, 2] characterize IgAN
membrane glycoprotein that is constitutively expressedin humans. Codeposition of IgA together with IgG
on the surface of rat mesangial cells (MCs) [11]. It provedand/or IgM is reported in 45 to 83% and 9 to 66% of
to be an excellent model for IgA-mediated glomerulopa-
thy because rats receiving ER4A exhibited hematuria
[10]. In our new model, quantitated amounts of IgAKey words: glomerulonephritis, IgA nephropathy, immunoglobulin A
and G, albuminuria, microhematuria. can be anchored in the renal mesangium without any
interference of mucosal compartments. In addition, thisReceived for publication August 18, 1998
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ing two antibodies with identical epitope specificity but
different class-determined activities. Therefore, we were
able to investigate the aggravating effect of IgG on IgA-




Phosphate-buffered saline (PBS; 10 mm sodium phos-
phate, pH 7.4, 0.15 m NaCl), (NH4)2SO4, H2O2, oxalic acid
(Merck, Darmstadt, Germany), Tween-20 (J.T. Baker
Chemicals Co., Deventer, The Netherlands), 2,29-amino-
Fig. 1. Albuminuria in rats injected with increasing amounts of ER4Gbis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS), bo-
on days 1 (h) and 7 (j) (depicted are averages 6 SD of N 5 3 pervine serum albumin (BSA), merthiolate, 2,7-diami-
dose).
nofluorene (DAF; Sigma Chemical Co., St. Louis, MO,
USA), fetal calf serum (FCS; GIBCO BRL, Grand Is-
land, NY, USA), dipsticks (Hema-Combisticks, Bayer
Diagnostics, Mijdrecht, The Netherlands), rat mono- Rats
clonal antibodies antimouse IgA heavy chain, rat mono- Studies were performed in young male Wistar rats
clonal antibodies antimouse IgG, and horseradish per- weighing approximately 150 g. The rats were housed in
oxidase (HRP)-conjugated rat monoclonal antibody accredited animal facilities, were fed pelleted food, and
against mouse k light chain (Sanbio, Uden, The Nether- had access to water ad libitum. Experiments were per-
lands) were obtained as indicated. Goat antimouse IgG formed in accord with the National Institutes of Health
FITC and goat antimouse IgA (Fc) FITC were purchased
Guide for the Care and Use of Laboratory Animals.
from Nordic (Tilburg, The Netherlands). FITC-conju-
gated mouse monoclonal antibodies directed against Generation and production of mouse IgG and IgA
monocytes/macrophages (ED1) were kindly provided by anti-Thy-1 antibodies
Dr. C.D. Dijkstra (Free University of Amsterdam, Am-
The generation of a mouse IgG anti-Thy-1.1-pro-sterdam, The Netherlands) [12]. Mouse IgG monoclonal
ducing hybridoma clone has been reported before [17].antibodies antihuman HLA-A, B, and C (W6/32) were
The mouse IgG producing clone (ER4G) was switchedobtained from American Type Culture Collection
to an IgA-producing clone (ER4A) by in vivo passage(Rockville, MD, USA). Monoclonal mouse IgA anti-
and in vitro sequential sublining in cytokine-containingDNP antibodies, MOPC315 have been described before
media [10].[13, 14]. Mouse monoclonal antibodies directed against
granulocytes and T cells (W3/13) were described pre- In vivo experiments
viously [15]. FITC-conjugated rabbit antirat C3 antibod-
To appreciate a possible contribution of ER4G onies were generated in our own laboratory. Monoclonal
ER4A-mediated glomerular inflammation, a limitingantibodies recognizing the proliferating cell nuclear anti-
dose of ER4G was combined with a high dose of ER4Agen (PCNA) in the late G1, S, G2, and M phases of the
able to induce hematuria. The reason to choose a limitingcell cycle [16] were obtained form Sigma Chemical Co.
dose of ER4G is that ER4G induces dose-dependentDr. W.G. Couser (Division of Nephrology, University of
renal inflammation alone. To determine the limiting doseWashington, Medical Center, Seattle, WA, USA) kindly
of ER4G, a dose response of ER4G (0, 0.1, 0.25, 0.5,provided mouse monoclonal antibodies directed against
0.75, or 1.0 mg/kg body wt) was administered into therat C6 and rat monoclonal antibodies directed against
renal artery [intra-arterial (i.a.)] of male Wistar rats (3rat C5b-9. These monoclonal antibodies were coupled
rats per dose). The urine of all of the rats was collectedto digoxygenin (DIG) according to the manufacturer’s
before and daily up to day 6 after the injection of ER4Ginstructions using DIG-NHS (Boehringer Mannheim,
and was assessed for albuminuria as described later inMannheim, Germany). HRP-conjugated Sheep F (ab9)
this article (Fig. 1). In addition, renal biopsies were ob-anti-DIG fragments were also from Boehringer. Tyra-
tained before and on day 1 and 7 after the injection ofmide-FITC was purchased from NEN-Dupont Research
ER4G.Products (Boston, MA, USA). Protein A-Sepharose 4B
In this study, 30 young, inbred, male Wistar ratsand HiLoad 26/60 Superdex 200 prep grade were pur-
weighing approximately 150 g were divided into fivechased from Pharmacia LKB Biotechnology (Uppsala,
Sweden). groups of six rats each. One group of rats received an
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i.a. injection of 7.5 mg/kg body wt of ER4A in saline kidney specimen, at least 20 glomeruli were selected by
a predetermined mechanical walk [20] and were evalu-alone on day 0; the second group received a limiting
dose of 0.38 mg/kg body wt (i.a.) of ER4G alone; the ated by light microscopy for extracellular matrix (ECM).
Using a superimposed grid on selected glomeruli, thethird group received an i.a. injection of 7.5 mg/kg body
wt of ER4A together with (simultaneously) a limiting percentage of ECM per glomerular cross section of each
biopsy was quantitated and subsequently subjected todose of 0.38 mg/kg body wt of ER4G in saline on the
same day. The fourth group received an i.a. injection of statistical analysis as described later in this article [20].
Kidney specimens were processed for immunofluo-the same volume of PBS alone. The fifth group (N 5 6
rats) served as a control group; three rats received ER4A rescence according to standard procedures. Briefly, rat
renal tissue was snap frozen in precooled isobutanol andat 7.5 mg/kg in the presence of 0.38 mg/kg control mouse
IgG antibodies (W6/32), and three rats received 0.38 stored in liquid nitrogen. Cryostat sections of 3 mm were
obtained and, after air drying, were fixed in acetone formg/kg ER4G in combination with 7.5 mg/kg of control
mouse IgA antibodies (MOPC315). 10 minutes at room temperature. The slides were washed
twice for seven minutes in PBS and were examined forTwenty-four hour urine was collected before the injec-
tions, on days 1, 7, and 17 after antibody administration. the presence of mouse IgA, mouse IgG, rat C3, and
infiltration of monocytes/macrophages in the glomeruliIn addition, kidney biopsies were taken from all rats
under halothane anesthesia before the start of the experi- using FITC-conjugated goat antimouse IgA, FITC-con-
jugated goat antimouse IgG, FITC-conjugated rabbitment, on days 1, 7, and 17, after which all rats were
sacrificed. Kidney biopsies were split in two; one half antirat C3, and FITC-conjugated ED1. Between the one-
hour incubation steps at room temperature, the slideswas used for immunofluorescence and the other half was
processed for light microscopy. were washed three times for seven minutes with PBS at
room temperature.
Preparation of nephritic elutes The total number of macrophages in at least 20 glo-
merular cross-sections per rat kidney was counted andBecause the possibility exists that simultaneous ad-
ministration of ER4G and ER4A might influence their expressed as the average number of macrophages per
glomerulus. Similarly, the total number of proliferatingmutual deposition in the kidney, we quantitated the
amounts of antibodies bound in kidneys. For this pur- cells in 10 rat glomeruli was quantitated after staining
kidney sections for the PCNA/cyclin. The glomerularpose, 15 Wistar rats were divided into five groups of
three rats each. One group received an i.a. injection of influx of polymorphonuclear cells (PMNs) was assessed
using FITC-labeled monoclonal antibody W3/13. Rat C67.5 mg/kg (body wt) of ER4A alone. One group received
ER4A (7.5 mg/kg body wt) in combination with 0.38 and rat C5b-9 were detected by staining kidney biopsies
using DIG-conjugated mouse monoclonal antirat C6 ormg/kg (body wt) of ER4G, and one group received
ER4A (7.5 mg/kg body wt) in combination with control mouse monoclonal antirat C5b-9 antibodies as described
previously [21]. Photographs were taken on Kodak TX-IgG antibodies (0.38 mg/kg body wt). One group of rats
received ER4G (0.38 mg/kg body wt) in combination 400 film on a Leitz microscope equipped with a 4 mm
BG 38 1 5 mm BG 12 filter for FITC.with control IgA antibodies (7.5 mg/kg body wt), and the
last group received ER4G alone (0.38 mg/kg body wt).
Quantitation of glomerular extracellular matrixAfter one hour, the kidneys of all rats were perfused
with 100 ml PBS by aortic puncture under halothane Quantitative estimates of the glomerular deposition
of PAS-positive ECM proved to be the most importantanesthesia. The kidneys were subsequently snap frozen
in isobutanol and stored at 2708C until further use. The structural correlate of renal function (r 5 0.524, P 5
0.0001) in renal biopsies of patients with various kidneyglomeruli from each group were isolated from pooled
cortices as described earlier [18], and bound antibodies diseases in our institute [20]. The amount of ECM in
biopsies of rats injected with ER4 monoclonal antibodieswere eluted from glomeruli by incubation in citrate
buffer, pH 2.5, for one hour at room temperature. The was quantitated using the same grid-counting method
[20]. In each biopsy, 20 glomeruli were evaluated, aver-amount of mouse IgA and mouse IgG that bound to the
kidneys was determined using isotype-specific enzyme- aged, and subjected to statistical analysis.
linked immunosorbent assays (ELISA) as described be-
Albuminuria and hematuriafore [10].
For the assessment of albuminuria, the rats were
Histology and immunofluorescence housed in metabolic cages, and albumin excretion was
determined in 24-hour urine samples containing 0.1%Renal tissue specimens (4 mm2) were fixed in methyl
Carnoy’s solution [19] and were paraffin embedded, sec- merthiolate by immunodiffusion using rat serum albu-
min (RSA) as a protein standard. Briefly, urinary RSAtioned, and stained with periodic acid-Schiff (PAS), he-
matoxylin-eosin (HE), or methenamine silver. In each was determined by rocket electrophoresis using rabbit
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Table 1. Average number of monocytes and macrophages per Effects of ER4G and ER4A in vivo
glomerular cross-section on days 1 and 7 after the
administration of ER4 monoclonal antibodies Immunofluorescence. All rats injected with the limiting
dose of ER4G revealed a weak positive mesangial stain-ER4G day 1 ER4G day 7
ing for mouse IgG in contrast to the strong mesangial
2 1 2 1
IgG staining in kidneys of rats that received 1 mg/kg
Dose ER4 mg/kg (as previously shown; Fig. 2) [10]. Infusion of ER4A to0 1.360.2 4.462.0 1.360.0 4.761.0
rats resulted in a mesangial deposition of IgA antibodies7.5 2.060.4 3.961.6 1.960.9 3.860.9
on day 1 (Fig. 3). Furthermore, the combination of IgGNo significant additive increase in the average number of ED11 cells was
detected on days 1 or 7 in the groups of rats receiving both ER4A and ER4G together with IgA resulted in comparable intensities of
as compared to groups of rats that had received an exclusive injection of PBS,
deposition of these antibodies as compared with singleER4A or ER4G. Depicted are averages 6 sd of 6 rats per group.
antibody injections.
No significant difference in the quantitation of kidney-
bound antibodies was observed between groups of rats
anti-RSA antibodies (produced in our laboratory). A injected with ER4A in the absence or presence of ER4G
1.0% agarose solution containing rabbit anti-RSA anti- or in the presence of control IgG antibodies. There was
bodies was poured on a glass plate and allowed to set. no significant difference in the amount of binding of
Wells were punched in the agarose (diameter 2.5 mm) ER4G in groups of rats injected with ER4G alone, ER4G
and filled with the appropriate predetermined urine dilu- in combination with control IgA antibodies, or ER4A
tion. The samples were subjected to electrophoresis for one hour after the infusion of the antibodies (data not
four hours at 40 mA, and subsequently, the plate was shown). On day 7, a declined staining for both IgG and
rinsed in PBS containing 2 mm ethylenediaminetetraace- IgA was observed.
tic acid (EDTA). Precipitin bands were visualized with Although the ER4G-receiving rats showed minor mes-
Amido black, and rocket heights were compared be- angial deposition for rat C3, the ER4A and the PBS-
tween the standard and the sample.
treated rats were essentially negative. In the rats receiv-
Hematuria was determined using dipsticks, with scal-
ing the combination of antibodies, a moderate increase ining of 0, 0 to 10, 25, 80, or 200 red blood cell (RBC)/ml
the intensity of staining for C3 was observed as comparedper sample tested.
with biopsies of rats with single ER4G antibody injec-
tions (data not shown). Furthermore, in biopsies of ratsStatistical analysis
injected with PBS, limiting ER4G or ER4A alone, noAll values are expressed as mean 6 sd unless stated
glomerular staining for rat C6 was found. However, onotherwise. Statistical analysis was performed using the
day 1, a marked, enhanced glomerular deposition of ratMann–Whitney U-test for the comparison of two unre-
C6 and rat C5b-9 was found in the combination grouplated groups. A P value less than 0.05 was considered
(Figs. 4 and 5, respectively). The staining for C6 andsignificant.
C5b-9 was absent seven days after the administration of
antibodies.
RESULTS The glomerular influx of monocytes was quantitated
and revealed that on day 1 ER4G-receiving rats had anMonoclonal IgG and IgA antibodies against Thy-1
average of 4.4 6 2.0 monocytes per glomerular crossWe have previously demonstrated clonality and unal-
section (Table 1). This increase in number of macro-tered epitope specificity of the mouse IgG and IgA anti-
phages was significant (P , 0.05) when compared withThy-1 monoclonal antibodies (indicated by ER4G and
control rats receiving PBS alone (1.3 6 0.2 macro-ER4A, respectively) by reciprocal inhibition analysis us-
phages). In the ER4A rats, no significant difference ining rat MCs, labeled ER4A, and unlabeled ER4A or
the number of ED1-positive cells as compared with theER4G. At maximum input, both ER4A and ER4G were
PBS rats was found on days 1 or 7 (2.0 6 0.4 and 1.9 6able to inhibit the binding of labeled ER4A to rat MCs
0.9, respectively). Furthermore, no significant additivein a dose-dependent fashion [10]. Furthermore, in vivo
increase in the average number of ED1-positive cellsdata clearly demonstrated that rats receiving ER4G re-
was observed in the combination group as comparedvealed a positive mesangial staining for mouse IgG,
with rats receiving one antibody alone (3.9 6 1.6 andwhereas rats that received ER4A alone exhibited a posi-
3.8 6 0.9 on days 1 and 7, respectively).tive reaction with anti-IgA on day 1 and 6 after injection
Albuminuria and hematuria. Before the start of the(data not shown) [10].
experiment, all rats had comparable normal levels ofER4G induces a dose-dependent albuminuria in rats
urinary RSA (ranging from 86 to 1728 mg/24 hr). The(Table 1). For this study, we determined the dose of
administration of limiting ER4G alone to rats resultedER4G that resulted in albuminuria of 4.0 6 0.3 mg albu-
min/24 hr on day 1 after the ER4G injection. in albuminuria of 4000 6 3000 mg albumin/24 hr on day
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Fig. 2. Immunofluorescence staining using FITC-conjugated goat antimouse IgG antibodies in glomeruli of rats injected with PBS, (A) a limiting
dose of ER4G (0.4 mg/kg; B) or an optimal dose of ER4G (1.0 mg/kg; C) on day 1 after injection (all, 3250).
Fig. 3. Immunofluorescence staining using FITC-conjugated goat antimouse IgA antibodies in kidney cross-sections of rats injected with PBS
(A) or 7.5 mg/kg ER4A (B) on day 1 after injection (all, 3250).
1 after injection. One week after the injection of ER4G compared with groups of rats with single antibodies or
PBS alone (Fig. 6). On day 17 after the start of thealone, rats still had albuminuria of 1380 6 467 mg/24 hr
(Fig. 6), returning to normal urinary RSA levels again experiment, all groups of rats receiving antibodies had
normal levels of urinary RSA excretion again (noton day 17 (not shown). Rats receiving PBS or ER4A
alone had 381.5 6 163 and 311 6 187 albumin/24 hr, shown). Rats receiving identical doses of control IgA
in combination with ER4G revealed albuminuria ofrespectively, on day 1. The combination of ER4A 1
ER4G resulted in 11,555 6 6018 mg albumin/24 hr on 3568 6 2500 mg albumin/24 hr on day 1 after injection.
This value did not differ significantly from rats receivingday 1, which was not significantly different from rats
receiving ER4G alone. However, on day 7, the group of ER4G alone. Rats that were treated with ER4A in com-
bination with control IgG antibodies did not exhibit lev-rats receiving the combination of ER4G and ER4A had
developed a significant (P , 0.02), synergistic increase els of albuminuria different from control PBS-treated
rats.in albuminuria (12,400 6 1500 mg albumin/24 hr) as
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Fig. 4. Immunofluorescence staining using a mouse monoclonal antibody directed against rat C6 on kidney cross-sections of rats injected with
PBS (A), a limiting dose of ER4G (B), ER4A (C), or a combination of a limiting dose of ER4G in the presence of ER4A (D) on day 1 after the
injection (all, 3250). Rat C6 was only detected in glomeruli of rats treated with the combination of anti-Thy-1 antibodies.
Hematuria was assessed using dipsticks (Table 2). On analyzed by light microscopy for histological abnormali-
ties, the rats injected with ER4G alone revealed focalday 1, both ER4A- and ER4G-treated rats exhibited
comparable hematuria (10 to 25 RBC/ml full urine). No MC lysis, diffuse and moderate MC proliferation, and
slight ECM expansion and microaneurysms on day 7detectable difference was found with the groups of rats
receiving the combination of ER4 isotypes on days 1 (Fig. 7B) after injection. Interestingly, the animals that
received ER4A alone only transiently exhibited slightlyand 7 (Table 2).
Light microscopy. When the biopsies of the rats were disrupted mesangial matrices with small open areas on
van Dixhoorn et al: Anti-Thy-1 isotypes and renal inflammation 2305
Fig. 5. Immunofluorescence staining using a mouse monoclonal antibody directed against rat C5b-9 on kidney cross-sections of rats injected with
PBS (A), a limiting dose of ER4G (B), ER4A (C), or a combination of a limiting dose of ER4G in the presence of ER4A (D) on day 1 after the
injection (all, 3250). Rat C5b-9 was only observed in glomeruli of rats treated with the combination of ER4 monoclonal isotypes.
day 1, whereas no severe abnormalities were observed alterations, the number of proliferating glomerular cells
was counted in at least 10 glomeruli per renal cross sec-on day 7 (Fig. 7C). However, in biopsies of rats receiving
ER4A in the presence of a limiting dose of ER4G, mod- tion and was averaged and subjected to statistical analy-
sis. The quantitation of the number of glomerular prolif-erate MC proliferation and increased mesangial ECM
were observed. Figure 7D shows a glomerular capillary erating cells was not significantly different between the
groups of rats studied (data not shown).collapse with adhesion of the glomerular capillary tuft
to Bowman’s capsule. To quantitate these histological Furthermore, glomerular ECM was quantitated in
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amounts of dimeric mouse IgA anti-Thy-1 monoclonal
antibodies together with quantitated but limiting mouse
IgG anti-Thy-1 antibodies are deposited specifically in
the rat glomerulus without any interference from the
mucosal compartments. We do want to emphasize some
potential caveats before extrapolating these data to
IgAN. Sera of patients with IgAN have been tested for
autoimmune reactivity with cultured MCs, but so far,
the presence of IgA antimesangial antibodies has not
been reported. An advantage of this study is the use of
a monoclonal antibody that had undergone a stimulated
isotype switch in vitro, so that antibodies with an identical
Fig. 6. Assessment of albuminuria as determined by rat serum albumin
epitope specificity but different class-determined activi-(RSA) excretion in urine of rats injected with ER4 monoclonal antibod-
ies seven days after antibody injection. A significant (P , 0.02; indicated ties were obtained. In this new model for IgA-mediated
by the asterisk), synergistic increase in albuminuria was found in the glomerulopathy, the aggravating effect of noninflamma-
combination group as compared with groups of rats injected with a
tory amounts of IgG on IgA-induced renal inflammationsingle antibody or PBS alone. Depicted are averages 6 sd of six rats
per group. could be studied, whereby the amount of kidney-bound
antibodies could be controlled through Thy-1 specificity.
Previously, we as well as other authors have demon-
strated that injection of mouse IgG2a anti-Thy-1 anti-Table 2. Hematuria as assessed by dipsticks in urine of rats injected
with ER4A in the absence or presence of a sub-nephritogenic bodies (ER4G) alone into rats, that is, 1 mg/kg body wt,
dose of ER4G results in a mesangial proliferative type of GN [10, 19,
27, 28]. The development of MC lysis and albuminuriaDay 1 Day 7
appears to be mainly complement dependent. In con-PBS 0 0
ER4G 10–25 10–25 trast, mesangial depositions of mouse IgA anti-Thy-1
ER4A 10–25 10–25 antibodies (ER4A) induces isolated hematuria [10]. No
ER4G1A 10–25 10
severe renal histopathological alterations are observed.
Here we demonstrate that the combined administration
of these antibodies induces a severe type of renal dam-
age, characterized by large glomerular complement com-PAS-stained kidney cross-sections of all rats using a grid-
ponent deposits and synergistically increased albumin-counting method [20]. Statistical analysis revealed that
uria.approximately 26.4 6 4.9% of a glomerulus of an un-
The limiting dose of ER4G was based on the level oftreated rat was occupied by ECM material (Fig. 8). In the
albuminuria, complement activation, influx of inflam-combination group, an additive, rather than a synergistic
matory cells, and histological changes of the glomerulus.increase, in ECM was observed (43.4 6 2.3, P , 0.05,
We established that, as expected, with increasing dosesas compared with rats receiving ER4A or ER4G alone
of ER4G, more complement was deposited in the glo-in which 33.5 6 2.4 and 32.9 6 3.4% of the glomerulus
meruli of rats, and simultaneously, these rats were morestains positive for ECM material, respectively).
proteinuric with more glomerular inflammatory cells and
increased glomerular sclerosis. However, the question
DISCUSSION in this study does not reside in the inflammatory capacity
of ER4G. We focused on the inflammatory potentialThe observation that codeposition of IgA together
with IgG and/or IgM in the renal mesangium is associ- of IgA in the presence of limiting, noninjurious IgG.
Apparently, in rats treated with mouse IgA in the pres-ated with a more rapid decline of the course of disease
in patients with IgAN has been documented by a number ence of limiting amounts of mouse IgG, complement
can be more effectively activated. The activation ofof investigators [22–24]. Studies in experimental animals,
especially mice, demonstrated that after oral immuniza- rat complement by mouse IgG2a antibodies proceeds
through the classic pathway, as demonstrated by C1 bind-tion with bovine g-globulin or gliadin IgA deposited
in the renal mesangium and hematuria occurred after ing [29]. In our in vivo model, the classic pathway con-
vertase C4bC2a is formed, subsequently cleaving C3 intoantigen challenge [25]. However, similar immunization
studies resulted in trace amounts of IgG and IgM also C3a and C3b. Because of the introduction in the mesan-
gial area of more condensed potential complement fix-in control mice [26]. Furthermore, these experimental
models for IgAN have the limitation that the ratio of ing sites, C3b can be fixed by both ER4A and ER4G.
This may result in formation of C3bBb, the alternativeIgA and IgG deposited in the mouse kidney cannot
be adequately controlled. In this study, quantitated pathway C3 convertase, resulting in more C3 cleavage
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Fig. 7. Light microscopy of rat kidney cross-sections of day 7 after administration of PBS (A), ER4G alone (B), ER4A alone (C), or the
combination of ER4A together with ER4G (D; methenamine silver staining, 3250). Mesangial cell proliferation and ECM expansion are indicated
by small arrowheads. Glomerular adhesion to Bowman’s capsule is indicated by the larger arrowhead.
products. Thus, we hypothesize that ER4G and ER4A body injection. It is therefore unlikely that a significant
deposition of IgA in the renal mesangium alters thecooperate in complement activation resulting in the gen-
eration of C5b-9. Apparently, detectable amounts of C3b flux of protein through the mesangium and subsequently
leads to increased mesangial deposits of IgG. Further-can only be observed in glomeruli of rats injected with
ER4G and ER4A, but not in rats treated with ER4A more, it is notable that the pattern of C6 and C5b-9
on day 1 appeared patchy, not involving all mesangialalone. It is evident from our study that participation
of the classic pathway in IgA-mediated glomerulopathy regions to the same degree. Still, the IgA and IgG depos-
its were diffuse. One explanation for this observation isinduces a more severe type of renal inflammation. Future
studies with properdin depletion will elucidate the rela- that at this time point parts of the mesangial area are
damaged by membrane attack complex formation ear-tive contribution of the classic and alternative pathway
on complement-mediated glomerulopathy. lier. The observed patchy pattern may hence be caused
by mesangiolytic glomerular areas, which do not stainWe established that the amount of kidney-bound anti-
bodies was not influenced by combined anti-Thy-1 anti- positively for C6 nor for C5b-9.
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tients with less C3c deposition showed less severe histo-
pathological damage of the glomerulus with a relatively
good renal function, suggesting that activation of the
complement system in IgAN patients largely determines
the degree of glomerular scarring and renal injury.
In conclusion, codeposition of anti-Thy-1 monoclonal
antibodies of the IgA and IgG subclass in the rat glomer-
ulus induces a more severe type of GN. This inflam-
matory reaction is mainly dependent on the degree of
complement activation, as reflected by an increased de-
position of C5b-9 in the mesangial area. These observa-
tions are in agreement with histopathological findingsFig. 8. Average extracellular matrix (ECM) score (6 SEM) in PAS-
in biopsies of patients with IgAN, and therefore, thisstained kidney biopsies (20 glomeruli per biopsy) of rats injected with
PBS, ER4A, ER4G, or the combination of antibodies on day 7. The experimental model for IgAN may provide us with better
group of rats receiving the combination of anti-Thy-1 antibodies re-
insight in the mechanisms leading to IgAN.vealed a significant (P , 0.05) additive increased ECM as compared
with rats receiving PBS or single antibody injections alone (indicated
by asterisk). Depicted are averages 6 sd of six rats per group. ACKNOWLEDGMENTS
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